Introduction
============

Prostate cancer (PCa) is the second most common cancer in men with its incidence and mortality increasing in recent years ([@b1-ol-0-0-8322]--[@b3-ol-0-0-8322]). As a heterogeneous disease, PCa is influenced by gene aberrations, cellular context and environmental factors ([@b4-ol-0-0-8322]). Analysis of gene expression profiles with high-throughput platforms are increasingly considered to be effective tools for researching oncology progression mechanisms. Many gene expression databases and PCa profiles have been built using microarray and sequence technology. Accumulating evidence has shown that multiple genes and signaling pathways participate in PCa tumor carcinogenesis, progression and recurrence ([@b5-ol-0-0-8322],[@b6-ol-0-0-8322]); however, the tumor\'s mechanisms require further study. Therefore, identifying effective biomarkers to better predict the diagnostic and prognostic levels of this malignancy is of vital importance.

Kinesins are a family of molecular motor proteins that travel along microtubule tracks, playing multiple roles in intracellular transport and cell division ([@b7-ol-0-0-8322]). Previous studies have revealed that kinesins have several biofunctions in tumor malignancies, such as development and progression ([@b8-ol-0-0-8322]). Multiple studies have shown that kinesin super-family protein 4A (KIF4A) plays critical roles in controlling spindle organization and completing cytokinesis chromosome alignment and chromosome condensation ([@b9-ol-0-0-8322]--[@b14-ol-0-0-8322]). Dysregulating KIF4A causes abnormal spindle separation and further induces aneuploidy, which can cause cells to gain or lose genetic material ([@b15-ol-0-0-8322]). In addition, aneuploidy is highly associated with cancer progression ([@b16-ol-0-0-8322]). KIF4A is reported to be overexpressed in many cancers, such as liver, lung, oral, and gastric cancers and is amplified in cervical cancer ([@b17-ol-0-0-8322]--[@b21-ol-0-0-8322]). KIF4A is considered to be an oncogene that prompts malignancy. Previous studies showed that overexpressed KIF4A inhibits cancer cell growth in the stomach ([@b22-ol-0-0-8322]); however, its clinical values and roles in PCa are unclear. In the present study, bioinformatic analysis was performed to study KIF4A expression patterns and investigate the relationship between KIF4A and clinical prognosis in PCa patients.

In the present study, we demonstrated that increased KIF4A expression may be a potential clinical and prognostic biomarker in PCa. Cox proportional hazards regression model analysis showed that increased KIF4A expression was correlated with clinicopathological PCa values. This KIF4A expression pattern could be used as a prognostic biomarker in PCa to predict poor patient outcomes.

Materials and methods
=====================

### Differential gene expression analysis (DGEA)

High-throughput genomic datasets were downloaded from the Gene Expression Omnibus (GEO) database (accession no. GSE32269 and GSE35988). Raw expression data were downloaded as a SOFT formatted family file. GENE-E software (version 3.0.215, Broad Institute, Inc., Cambridge, MA, USA) was used to perform the DGEA. We used a t-test to identify differential expressed genes (DEGs) with a change ≥2-fold and P\<0.05 was considered to indicate a statistically significant difference.

### Patients samples

Clinical information was obtained from the Taylor dataset (including 150 PCa tissues and 29 adjacent non-cancerous prostate tissues; accession no. GSE21032), TCGA dataset \[498 PCa tissues with no normal prostate tissue; Prostate Adenocarcinoma (TCGA, Provisional) <http://www.cbioportal.org/study?id=prad_tcga#summary>\] and Michigan dataset \[50 metastatic castration-resistant prostate cancer (CRPC) and 11 high-grade localized PCa tissues; <http://www.cbioportal.org/study?id=prad_mich#summary>\] ([@b23-ol-0-0-8322]--[@b25-ol-0-0-8322]). The Taylor and Michigan datasets were used to investigate the KIF4A mRNA expression profile, while the Taylor and TCGA datasets were used to perform further survival analysis.

### Statistical analysis

Statistical analyses were performed using SPSS version 17.0 software for Windows (SPSS Inc., Chicago, IL, USA). We used an independent Student\'s t-test to analyze the results and data expressed as the mean ± standard deviation (SD). The Kaplan-Meier curve method was conducted for survival analysis. Cox proportional hazard regression models were constructed to determine the prognostic value of KIF4A expression for biochemical recurrence-free survival. First, we analyzed connections between biochemical recurrence-free survival and potential prognostic factors, including Gleason score, prostate-specific antigen (PSA), pathological stage, age and clinical stage, considering one factor at a time and all factors as continuous parameters. Second, multivariate Cox analysis was applied using backward stepwise procedures that always forced KIF4A expression into the model. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identifying upregulated genes in CRPC

DGEA was analyzed from two datasets (GSE32269 and GSE35988). In the Cai dataset (GSE32269), 22 primary hormone-dependent PCa samples and 29 metastatic CRPC samples were analyzed using GENE-E software, and DEGs lists were identified. A total of 279 genes were identified to be differentially expressed, with thresholds of P\<0.05 and fold changes ≥2.0 or ≤-2, which contained 220 upregulated and 59 downregulated genes. In the Grasso dataset (GSE35988), we analyzed differential gene expression between 59 localized PCa samples and 35 metastatic CRPC samples. In total, 430 upregulated and 1,001 downregulated genes were chosen ([Fig. 1A](#f1-ol-0-0-8322){ref-type="fig"}). Next, we calculated the intersection of two datasets via Venn diagrams, and 26 genes were commonly upregulated in these datasets ([Fig. 1B](#f1-ol-0-0-8322){ref-type="fig"}; [Table I](#tI-ol-0-0-8322){ref-type="table"}).

### Increased KIF4A expression in human PCa and CRPC tissues

Among the 26 commonly upregulated genes, androgen receptor (AR) was broadly considered to contribute to castration-resistant disease progression via multiple mechanisms including AR overexpression. Polycomb protein enhancer of zeste homolog 2 (EZH2) as a methyltransferase in the PRC2 complex (Polycomb Repressive Complex 2) is regularly overexpressed in several human cancers, particularly CRPC. KIF4A (abnormal spindle microtubule assembly) is associated with poor clinical prognosis in most tumors and may be a biomarker for predicting poor BCR-free survival in PCa patients. Interestingly, 6 genes (KIF11, KIF18B, KIF14, KIF4A, KIF2C, and KIF20A) from the kinesin superfamily are motor proteins that convert chemical energy into mechanical force ([@b21-ol-0-0-8322]). Previous studies reported that the KIF4 subfamily was vitally important for tumor development and progression ([@b26-ol-0-0-8322]--[@b28-ol-0-0-8322]). We performed KIF4A gene expression profiles on the Taylor and Michigan datasets to further evaluate the dysregulation ([Fig. 1C](#f1-ol-0-0-8322){ref-type="fig"}). In the Taylor dataset, we confirmed that KIF4A expression increased significantly with tumor progression (P\<0.001), and KIF4A was significantly upregulated in metastatic CRPC compared to localized PCa in the Michigan dataset (P\<0.003). Moreover, we examined the connection of KIF4A mRNA expression with different clinic-pathological characteristics according to Taylor and TCGA dataset ([Table II](#tII-ol-0-0-8322){ref-type="table"}). The results showed that patients with high Gleason score (≥8), short overall survival time, positive PSA failure had upregulated expression levels than those with low Gleason score (\<8), long over survival time, negative PSA failure (P\<0.001, in both datasets).

### High KIF4A expression as a prognostic factor of human PCa

Biochemical recurrence (BCR) is defined as a surrogate endpoint following radical prostatectomy. As with overall survival, BCR-free survival is vital to PCa patients, and it is clinically used to identify those who would benefit from early initiation of salvage treatment for additional therapy. We used the Kaplan-Meier curve method to evaluate the relationship between KIF4A expression and both overall and BCR-free survival in PCa datasets. We used the median KIF4A mRNA expression level as the cutoff point to split all samples into KIF4A-high (n=248, in the TCGA dataset; n=74, in the Taylor dataset) and KIF4A-low (n=247, in the TCGA dataset; n=76, in the Taylor dataset) groups. We confirmed that the BCR-free survival between KIF4A-high and KIF4A-low group samples was statistically significant (P\<0.001, in the TCGA dataset; P=0.003, in the Taylor dataset, [Fig. 2 A, C](#f2-ol-0-0-8322){ref-type="fig"}), and overall survival in the Taylor dataset was statistically significant (P=0.004, [Fig. 2B](#f2-ol-0-0-8322){ref-type="fig"}); however, overall survival in the TCGA dataset did not significantly differ (P=0.539, [Fig. 2D](#f2-ol-0-0-8322){ref-type="fig"}).

To further discuss KIF4A\'s prognostic value in PCa, we conducted univariate and multivariate Cox proportional hazards regression to verify KIF4A\'s clinical prognostic value in PCa datasets ([Tables III](#tIII-ol-0-0-8322){ref-type="table"} and [IV](#tIV-ol-0-0-8322){ref-type="table"}). We confirmed that KIF4A (P\<0.001 in the Taylor dataset), the Gleason score (P\<0.001 in both datasets), PSA (P=0.009 in the Taylor dataset) and pathological stage (P\<0.001 in the Taylor dataset) were appropriate for being considered as prognosis factors for BCR-free survival via univariate analysis. Next, we performed multivariate analysis and found that high KIF4A expression levels (P=0.005 in the Taylor datasets), Gleason scores (P=0.003 in the Taylor dataset, P\<0.001 in TCGA dataset), PSA (P=0.010 in the Taylor dataset) and pathological stage (P=0.004 in the Taylor dataset) are potentially independent factors for predicting shorter BCR-free survival. Due to the number of deceased patients in TCGA dataset (10 deaths in 499 samples), KIF4A\'s clinical prognostic value in overall survival still need to be studied in the future.

Discussion
==========

PCa has imposed a considerable economic burden on our society ([@b29-ol-0-0-8322]). Although many PCa patients have benefitted from improved techniques such as PSA screening, the time between tumor progression onset and BCR varies ([@b30-ol-0-0-8322]). Most castration-resistant PCa patients eventually relapse, resulting in metastasis and invasion, and because no effective treatments are currently available, their prognosis declines and eventually results in death. Therefore, identifying reliable biomarkers is vitally important for predicting recurrence and prognosis. To our knowledge, abnormally increased KIF4A expression has been reported in lung, oral, cervical, gastric and liver cancers ([@b17-ol-0-0-8322]--[@b21-ol-0-0-8322]); however, no research has been conducted on KIF4A in prostate neoplasms.

KIF4A mRNA and protein were reported to be significantly upregulated *in vitro*, and KIF4A protein expression was found to be significantly overexpressed in primary oral squamous cell carcinomas, which was closely correlated with tumor size ([@b17-ol-0-0-8322]). Further research demonstrated that KIF4A was a diagnostic/prognostic biomarker that was highly transactivated in many lung cancers by cDNA microarray, tumor tissue microarray, and immunohistochemical staining and was associated with male sex, non-adenocarcinoma histology, and shorter survival for the lung cancer patients ([@b18-ol-0-0-8322]). KIF4A was also reported to be upregulated in cervical cancer by cDNA array comparative genomic hybridization (aCGH) analysis ([@b19-ol-0-0-8322]). In addition, Hou *et al* demonstrated that KIF4A was overexpressed in hepatocellular carcinoma (HCC) tissue, which was significantly associated with survival time and clinical information (stage, metastasis and tumor dimension). Further functional analysis of siRNA-mediated silencing and KEGG pathway enrichment analysis showed that KIF4A promoted HCC cell growth and metastasis by mediating cell cycle-related and p53 signaling pathways ([@b20-ol-0-0-8322]). In the present study, using DGEA we found that KIF4A was highly expressed in CRPC, and further survival analysis showed that KIF4A may be an important oncogene. We investigated KIF4A gene expression profiles in different PCa datasets and confirmed that the KIF4A expression level was significantly increased in PCa samples, especially those in advanced pathological stages. To further validate the representativeness of its prognostic value in PCa, we conducted Kaplan-Meier survival analysis and Cox proportional hazards regression. The results showed that increased KIF4A expression was correlated with adverse BCR-free survival.

Furthermore, KIF4A overexpression enhanced migration and proliferation in lung cancer and HCC ([@b18-ol-0-0-8322],[@b20-ol-0-0-8322]), and KIF4A was found to control cellular proliferation via spindle assembly checkpoint (SAC) activation ([@b17-ol-0-0-8322]--[@b20-ol-0-0-8322]). Recent studies have revealed that the KIF4 subfamily is important in tumor development and progression ([@b9-ol-0-0-8322]--[@b14-ol-0-0-8322]). KIF4A plays critical roles in controlling spindle organization and completing cytokinesis chromosome alignment and chromosome condensation. Dysregulated KIF4A may induce cellular aneuploidy, causing cells to gain or lose genetic material ([@b15-ol-0-0-8322]). KIF4A is reported to be overexpressed in many cancers, and the present study showed that in PCa, KIF4A was overexpressed and may indicate poor prognosis. We innovatively used bioinformatic analysis in different datasets to cross-validate and screen possible genes that may potentially function as novel prognostic biomarkers. In addition, studies have demonstrated that several KIF family proteins are involved in developing drug resistance in cancer cells ([@b31-ol-0-0-8322]). Liu *et al* showed silencing MPHOSPH1 (also referred to as KIF20B) plus chemotherapy in HCC greatly improved antitumor treatment ([@b32-ol-0-0-8322]). Therefore, a combined strategy that targets KIF4A during PCa treatment may provide great efficacy. KIF4A is considered to be an oncogene that prompts malignancy; however, the mechanisms of KIF4A influencing PCa progression and prognosis still need further study.

In summary, our data showed for the first time that KIF4A was overexpressed in PCa, especially in CRPC. Increased KIF4A expression significantly predicted worse BCR-free survival and has the potential to be a prognostic PCa biomarker for predicting poor patient outcomes. Although the mechanism of increased KIF4A expression in PCa requires further study, KIF4A may serve as a therapeutic target for PCa.
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###### 

Commonly upregulated genes list.

             Cai dataset   Grasso dataset          
  ---------- ------------- ---------------- ------ --------------
  AR         2.17          1.19×10^−14^     2.1    2.67×10^−08^
  ASPM       2.15          1.24×10^−12^     3.99   7.95×10^−19^
  BIRC5      1.75          6.06×10^−11^     2.53   6.12×10^−14^
  BUB1       1.85          5.21×10^−15^     2.3    6.28×10^−11^
  CENPA      1.53          1.52×10^−12^     3.06   1.34×10^−11^
  CENPF      1.55          9.40×10^−14^     3.5    6.98×10^−09^
  DDIT4      1.96          1.43×10^−10^     2.06   1.77×10^−13^
  ESPL1      1.50          2.38×10^−10^     2.39   4.72×10^−19^
  EZH2       1.79          2.81×10^−13^     2.05   6.60×10^−15^
  FOXM1      1.53          3.08×10^−11^     2.63   3.15×10^−18^
  GTSE1      1.27          3.08×10^−09^     2.47   4.20×10^−11^
  HBG1       3.39          6.40×10^−14^     2.03   6.23×10^−05^
  IBSP       3.69          1.92×10^−12^     2.61   8.29×10^−04^
  KIAA0101   1.53          1.04×10^−10^     4.20   3.11×10^−03^
  KIF11      1.30          5.87×10^−10^     2.83   5.82×10^−15^
  KIF14      1.48          9.75×10^−15^     2.29   3.40×10^−04^
  KIF18B     1.54          1.27×10^−09^     2.69   2.09×10^−11^
  KIF20A     2.22          7.21×10^−13^     2.33   5.10×10^−12^
  KIF2C      1.17          2.90×10^−12^     2.52   1.90×10^−19^
  KIF4A      2.15          4.84×10^−17^     2.06   5.01×10^−13^
  MELK       1.77          1.03×10^−10^     2.26   9.06×10^−11^
  NUSAP1     1.90          2.22×10^−11^     2.08   5.21×10^−10^
  POLQ       1.38          3.71×10^−11^     2.67   1.22×10^−14^
  PTTG1      1.50          3.43×10^−13^     2.24   3.63×10^−16^
  SPAG5      1.26          8.53×10^−10^     2.71   1.09×10^−22^
  TPX2       1.94          1.01×10^−10^     2.45   3.08×10^−15^

EZH2, polycomb protein enhancer of zeste homolog 2.

###### 

Connection of KIF4A expression with clinicopathological characteristics of PCa in Taylor dataset and TCGA dataset.

                       Taylor dataset ([@b23-ol-0-0-8322])   TCGA dataset ([@b25-ol-0-0-8322])                                  
  -------------------- ------------------------------------- ----------------------------------- --------- ----- -------------- ---------
  KIF4A expression                                                                                                              
    Benign             29                                    5.97±0.23                                     --                   
    PCa                150                                   6.23±0.35                           \<0.001   498   0.121±1.569    --
  Serum PSA                                                                                                                     \<0.001
    \<4 (ng/ml)        24                                    6.21±0.34                                     411   0.011±1.000    
    ≥4 (ng/ml)         123                                   6.21±0.32                           0.977     27    1.517±5.048    
  Age, years                                                                                                                    0.306
    \<66               124                                   6.21±0.33                                     352   0.075±1.664    
    ≥66                26                                    6.31±0.41                           0.201     143   0.235±1.300    
  Pathological stage                                                                                                            \<0.001
    \<T3A              86                                    6.16±0.24                                     186   −0.300±0.480   
    ≥T3A               55                                    6.27±0.42                           0.056     302   0.307±1.245    
  Gleason score                                                                                                                 \<0.001
    \<8                117                                   6.14±0.24                                     290   −0.255±0.528   
    ≥8                 22                                    6.50±0.47                           \<0.001   205   0.653±2.252    
  Overall survival                                                                                                              \<0.001
    Alive              131                                   6.18±0.29                                     485   0.069±1.068    
    Decease            19                                    6.57±0.51                           \<0.001   10    2.653±7.752    
  PSA failure                                                                                                                   \<0.001
    Negative           104                                   6.13±0.24                                     398   −0.032±0.904   
    Positive           36                                    6.39±0.43                           \<0.001   91    0.524±1.508    

-, lack of relative information. KIF, kinesin super-family protein; PCa, prostate cancer; PSA, prostate-specific antigen.

###### 

Prognostic value of KIF4A mRNA expression level for the BCR-free survival via Cox proportional hazards model.

                          Taylor dataset ([@b23-ol-0-0-8322])   TCGA dataset ([@b25-ol-0-0-8322])                          
  ----------------------- ------------------------------------- ----------------------------------- ---------------------- ---------
  Univariate analysis                                                                                                      
    KIF4A mRNA            3.76 (2.086--6.779)                   \<0.001                             1.200 (0.996--1.445)   0.055
    Gleason score         2.665 (1.879--3.779)                  \<0.001                             1.730 (1.300--2.302)   \<0.001
    PSA                   1.005 (1.001--1.008)                  0.009                               --                     
    Pathological stage    3.143 (1.961--5.038)                  \<0.001                             1.190 (0.681--2.080)   0.541
    Age                   1.024 (0.973--1.076)                  0.363                               0.992 (0.960--1.026)   0.651
    Clinical stage        1.429 (0.808--2.525)                  0.219                               --                     
  Multivariate analysis                                                                                                    
    KIF4A mRNA            4.591 (1.584--13.309)                 0.005                               1.436 (1.271--1.623)   0.051
    Gleason score         1.844 (1.240--2.741)                  0.003                               2.202 (1.769--2.741)   \<0.001
    PSA                   1.005 (1.001--1.009)                  0.010                               --                     
    Pathological stage    2.198 (1.281--3.770)                  0.004                               2.590 (1.717--3.908)   0.067
    Age                   1.024 (0.974--1.077)                  0.837                               1.027 (0.925--1.060)   0.589
    Clinical stage        1.415 (0.799--2.505)                  0.514                               --                     

-, lack of relative information. KIF, kinesin super-family protein; BCR, biochemical recurrence; PSA, prostate-specific antigen.

###### 

Prognostic value of KIF4A mRNA expression level for the overall survival via Cox proportional hazards model.

                          Taylor dataset ([@b23-ol-0-0-8322])   TCGA dataset ([@b25-ol-0-0-8322])                          
  ----------------------- ------------------------------------- ----------------------------------- ---------------------- -------
  Univariate analysis                                                                                                      
    KIF4A mRNA            38.090 (7.044--205.973)               \<0.001                             0.610 (0.174--2.134)   0.439
    Gleason score         1.127 (0.743--1.710)                  0.574                               1.730 (1.300--2.302)   0.074
    PSA                   1.005 (1.000--1.010)                  0.067                               --                     
    Pathological stage    1.206 (0.454--3.205)                  0.707                               0.129 (0.015--1.095)   0.061
    Age                   1.048 (0.960--1.144)                  0.294                               0.993 (0.882--1.118)   0.911
    Clinical stage        1.955 (0.757--5.065)                  0.168                               --                     
  Multivariate analysis                                                                                                    
    KIF4A mRNA            41.798 (9.665--151.730)               \<0.001                             --                     --
    Gleason score         1.844 (1.240--2.741)                  0.003                               --                     --
    PSA                   1.006 (1.001--1.010)                  0.013                               --                     --
    Pathological stage    --                                    --                                  --                     --
    Age                   --                                    --                                  --                     --
    Clinical stage        --                                    --                                  --                     --

-, lack of relative information. KIF, kinesin super-family protein; BCR, biochemical recurrence; PSA, prostate-specific antigen.
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